This company has been marked as potentially delisted and may not be actively trading. NASDAQ:INNT Innovate Biopharmaceuticals (INNT) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisCompetitorsHeadlinesTrendsBuy This Stock About Innovate Biopharmaceuticals Stock (NASDAQ:INNT) 30 days 90 days 365 days Advanced Chart Get INNT alerts:Sign Up Key Stats Today's Range N/A50-Day Range$0.56▼$1.4252-Week Range N/AVolume18 shsAverage Volume525,982 shsMarket Capitalization$8 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Innovate Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company's lead product candidate is INN-202 that has completed Phase IIb clinical trial for the treatment of celiac disease. It also develops INN-108, which has completed Phase I clinical trial to treat mild-to-moderate ulcerative colitis; INN-217 for the treatment of non-alcoholic steatohepatitis and microbiome; and INN-289 to treat crohn's disease, as well as product for the treatment of alcoholic steatohepatitis (ASH). In addition, the company holds rights for INN-329, a formulation of secretin that is used to enhance visualization in magnetic resonance cholangiopancreatography procedures that is in Phase III clinical trial. The company has a research collaboration with Massachusetts General Hospital for the treatment of ASH. Innovate Biopharmaceuticals, Inc. is based in Raleigh, North Carolina. Read More Receive INNT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Innovate Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address INNT Stock News Headlines1Elevan Biopharmaceuticals, Inc. Announces the Development of Its Next-Generation Peptide Therapeutics Headquarters in Fishers, IndianaJune 17, 2025 | finance.yahoo.comVascarta Receives FDA Orphan Drug Designation for Vasceptor® in the Treatment of Sickle Cell DiseaseJune 12, 2025 | tmcnet.comThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.July 14 at 2:00 AM | Brownstone Research (Ad)Tagomics awarded £860 k Innovate UK Biomedical Catalyst grant for detection of colorectal cancerJune 10, 2025 | msn.comContext Therapeutics Names Dr. Karen Smith as Interim Chief Medical OfficerMay 10, 2025 | msn.comInnovent Biologics: Innovent Announces 2024 Annual Results and Business UpdatesMarch 26, 2025 | finanznachrichten.deLirum Therapeutics Announces Debut of LX-101 Results in Thyroid Eye Disease, Selected for Presentation at the 2025 NANOS Annual MeetingMarch 19, 2025 | markets.businessinsider.comMumbai Biocluster: Biologics Conference 2025 Concludes Successfully, Setting New Benchmarks in Biopharmaceutical Innovation and CollaborationFebruary 14, 2025 | finanznachrichten.deSee More Headlines INNT Stock Analysis - Frequently Asked Questions How were Innovate Biopharmaceuticals' earnings last quarter? Innovate Biopharmaceuticals Inc (NASDAQ:INNT) issued its quarterly earnings data on Monday, March, 18th. The company reported ($0.11) earnings per share for the quarter, meeting the consensus estimate of ($0.11). What other stocks do shareholders of Innovate Biopharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Innovate Biopharmaceuticals investors own include 9 Meters Biopharma (NMTR), NIO (NIO), Corbus Pharmaceuticals (CRBP), Energy Transfer (ET), Iterum Therapeutics (ITRM), Meta Platforms (META) and Micron Technology (MU). Company Calendar Last Earnings3/18/2019Today7/14/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:INNT CIK1551986 Webwww.innovatebiopharma.com Phone919-275-1933FaxN/AEmployees8Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$27.05 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-234.42% Debt Debt-to-Equity RatioN/A Current Ratio0.35 Quick Ratio0.35 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.27) per share Price / BookN/AMiscellaneous Outstanding Shares41,325,000Free FloatN/AMarket Cap$8 thousand OptionableNot Optionable Beta-0.39 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report This page (NASDAQ:INNT) was last updated on 7/14/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredAn extra $1,000 per month?A little-known Title 15 provision could let you collect instant payouts — $100 to $1,000 — directly from your ...TradeSmith | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Innovate Biopharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Innovate Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.